RPI-78M is ReceptoPharm’s drug candidate for the treatment of autoimmune and neurological disorders and RPI-MN is its leading antiviral drug candidate.
Paul Reid, CEO of ReceptoPharm, said: “This collaboration with the Centers for Disease Control and Prevention (CDC) allows us to analyze various formulas for both RPI-78M and RPI-MN as possible treatments for rabies.
“Our goal with this study is to better understand the mechanism of action of our leading drug candidates and to determine their potential for treating advanced rabies infections.”